The study of the membrane-protective potential of the combination of 2-ethyl-6-methyl-3-hydroxypyridine-succinate and citicoline

Solovyeva, E. Yu.; Карнеев, А. Н.; Чеканов, А. В.; Baranova, O. A.; Shchelkonogov, V. A.; Sinebryukhova, A. M.; Farakhova, K. I.; Сорокоумова, Г. М.

doi:10.17116/jnevro20181181118-22

Cited by 7 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experimental studies suggest neuromodulatory effects and protective roles of Citicoline on RGCs [43–45] due to its membrane protective potential [46] and ability to stimulate certain neurotransmitters including dopamine, known to be largely expressed in both the retina and post-retinal visual pathways [47–50].…”

Section: Introductionmentioning

confidence: 99%

Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study

et al. 2019

View full text Add to dashboard Cite

Purpose To evaluate whether treatment with Citicoline in oral solution (OS-Citicoline) would increase visual function, retinal ganglion cells (RGCs) function, and neural conduction along visual pathways (neuroenhancement), and/or induce preservation of RGCs fibers’ loss (neuroprotection) in non-arteritic ischemic optic neuropathy (NAION), a human model of neurodegeneration. Methods Thirty-six patients with NAION and 20 age-matched controls were enrolled. Nineteen NAION patients received 500 mg/day of OS-Citicoline for a 6-month period followed by 3-month of wash-out (NC Group); 17 NAION patients were not treated (NN Group) from baseline to 9 months. In all subjects at baseline, and in NC and NN eyes at 6 and 9 months of follow-up, we assessed Visual Acuity (VA), Pattern Electroretinogram (PERG), Visual Evoked Potentials (VEP), retinal nerve fiber layer thickness (RNFL-T), and Humphrey 24–2 visual field mean deviation (HFA MD). Mean differences were statistically evaluated with ANOVA between Groups, and linear correlations were analysed with Pearson’s test. Results At 6 months, significant differences between groups for all parameters were observed (ANOVA, p<0.01). In NC eyes, VA increased, PERG responses increased, VEP recordings improved and were significantly correlated with increases in HFA MD (p<0.01), and RNFL-T was unmodified or improved. In contrast, in NN eyes, VA, PERG, VEP responses, RNFL-T, and HFA MD were further worsened. Significant differences were still present at 9-month follow-up in the NN Group and after 3 months of OS-Citicoline wash-out in NC eyes. Conclusions OS-Citicoline treatment induced neuroenhancement (improvement in RGCs function and neural conduction along visual pathways related to improvement of visual field defects) and neuroprotection (unmodified or improved RNFL morphological condition) in a human model of NAION involving fast RGCs degeneration. Trial registration ClinicalTrials.gov NCT03758118 .

show abstract

Section: Introductionmentioning

confidence: 99%

Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study

et al. 2019

View full text Add to dashboard Cite

show abstract

Chronic cerebral ischemia and headache in patients in primary care physician's practice

Shishkova

Адашева

2021

RJTAO

View full text Add to dashboard Cite

Cognitive and emotional disorders in patients with chronic heart failure: prospects for detection and correction

Shishkova

2022

RJTAO

View full text Add to dashboard Cite

The article presents current data on the prevalence of anxiety, depressive disorders and cognitive impairment in patients with chronic heart failure (CHF). Data on the main pathogenetic mechanisms of the relationship in the development of emotional and cognitive impairments in patients with CHF are summarized. Recommendations for screening for cognitive and emotional disorders in this patient are given. The prospects for the correction of these disorders in patients with CHF are discussed, including within the framework of interdisciplinary cooperation.

show abstract

The study of the membrane-protective potential of the combination of 2-ethyl-6-methyl-3-hydroxypyridine-succinate and citicoline

Cited by 7 publications

References 29 publications

Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study

Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study

Chronic cerebral ischemia and headache in patients in primary care physician's practice

Cognitive and emotional disorders in patients with chronic heart failure: prospects for detection and correction

Contact Info

Product

Resources

About